KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) EBT Margin (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of EBT Margin data on record, last reported at 89.97% in Q4 2025.

  • For Q4 2025, EBT Margin fell 9682.0% year-over-year to 89.97%; the TTM value through Dec 2025 reached 341.28%, down 14030.0%, while the annual FY2025 figure was 341.28%, 14030.0% down from the prior year.
  • EBT Margin reached 89.97% in Q4 2025 per PACB's latest filing, up from 97.86% in the prior quarter.
  • Across five years, EBT Margin topped out at 6.85% in Q4 2024 and bottomed at 1147.62% in Q1 2025.
  • Average EBT Margin over 5 years is 229.35%, with a median of 170.58% recorded in 2021.
  • The widest YoY moves for EBT Margin: up 37591bps in 2025, down -94619bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 189.22% in 2021, then crashed by -63bps to 308.5% in 2022, then surged by 54bps to 141.78% in 2023, then surged by 105bps to 6.85% in 2024, then tumbled by -1413bps to 89.97% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 89.97% in Q4 2025, 97.86% in Q3 2025, and 105.35% in Q2 2025.